Trial Profile
The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Arteriovenous Fistulae in Patients With End Stage Renal Failure
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Capsaicin (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms Qutenza for painful fistulae v1.0
- 18 Jul 2020 Status changed from recruiting to discontinued.
- 08 Nov 2016 Planned End Date changed from 1 Jul 2014 to 1 Aug 2017.
- 08 Nov 2016 Status changed from not yet recruiting to recruiting.